The ethics of disease-modifying drugs targeting Alzheimer disease: response to our commentators.

Autor: Gustavsson E; Centre for Applied Ethics, Department of Culture and Society, Linköping University, Linköping, Sweden erik.gustavsson@liu.se.; The National Centre for Priorities in Health, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden., Raaschou P; Clinical Pharmacology Unit, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Lärfars G; Health and Medical Care Administration, Stockholm, Sweden., Sandman L; The National Centre for Priorities in Health, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden., Juth N; Stockholm Centre of Healthcare Ethics, LIME, Karolinska Institute, Stockholm, Sweden.
Jazyk: angličtina
Zdroj: Journal of medical ethics [J Med Ethics] 2022 Mar; Vol. 48 (3), pp. 193. Date of Electronic Publication: 2022 Feb 03.
DOI: 10.1136/medethics-2022-108157
Abstrakt: Competing Interests: Competing interests: None declared.
Databáze: MEDLINE